ASCO oncology conference: ImmunoGen (IMGN) +4.9% after it says its SAR3419 compound for...

|By:, SA News Editor

ASCO oncology conference: ImmunoGen (IMGN) +4.9% after it says its SAR3419 compound for non-Hodgkin's lymphoma and other B-cell malignancies showed improved safety and performance in a Phase I trial that used a modified dosing schedule. The drug has been licensed to Sanofy (SNY +0.75%)